Document registry — page 28
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 May 2024 -
Randomised withdrawal, phase 3 study of Tirzepatide in obesity randomising 670 participants over 52 weeks after a 36-week open-label lead-in. Primary result: Continued…
High18 May 2024 -
Randomised, open-label, active-controlled, phase 3 study of Liraglutide in type 2 diabetes randomising 464 participants over 26 weeks. Primary result: Difference −0.33…
High18 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low17 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 May 2024 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 May 2024 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 May 2024 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low12 May 2024 -
Synthetic pentadecapeptide derived from a gastric juice protein sequence. The proposed mechanism is angiogenic and cytoprotective action through VEGF receptor 2 transactivation and nitric-oxide-pathway modulation…
Very low11 May 2024 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low11 May 2024 -
Randomised crossover, phase 1 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low11 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in obesity randomising 272 participants over 36 weeks. Primary result: Mean change up to…
Moderate09 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Glutathione in cognition over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 May 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low08 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash randomising 190 participants over 52 weeks. Primary result: Resolution in 44 % to 62 %…
Low06 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low04 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity and type 2 diabetes randomising 938 participants over 72 weeks. Primary result…
High02 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of GHK-Cu in wound healing over 12 weeks. Primary result: Directionally consistent with the companion study…
Low02 May 2024 -
Single-arm open-label, phase 3 study of Tirzepatide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low02 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low02 May 2024 -
Consultation on the draft monograph for GHRP-6, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
01 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low01 May 2024 -
A disorder of glucose regulation characterised by insulin resistance with relative insulin deficiency, diagnosed by glycated haemoglobin, fasting plasma glucose or oral…
28 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Pramlintide in obesity randomising 411 participants over 16 weeks. Primary result: A weight reduction of…
Low27 Apr 2024 -
Randomised crossover study of DSIP in sleep over not recorded. Primary result: Historical crossover studies in small samples reported inconsistent effects on sleep…
26 Apr 2024 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low26 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low25 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Apr 2024 -
Slowed gastric transit, considered here both as a pharmacodynamic mechanism and as an adverse-effect surface relevant to procedural and anaesthetic risk.
23 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low22 Apr 2024 -
Single-arm open-label, phase 3 study of Exenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low20 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Apr 2024 -
Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide). Ghrelin receptor agonism producing growth-hormone release. Its approved use is a single-dose provocative diagnostic test, for which the acute…
Low17 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Apr 2024 -
Randomised, double-blind, placebo-controlled study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low16 Apr 2024 -
Randomised crossover, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low15 Apr 2024
page 28 of 41